Drugs / UCT-01-097
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04761601 | Mar 2021 → Feb 2024 | neoplastic disease or syndrome | 1200 Pharma, LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCT-01-097 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04761601 ↗ |
| Action | Inhibit | “Orally available kinase inhibitor” NCT04761601 ↗ |
| Route | Oral | “Orally available” NCT04761601 ↗ |